← All organizations
Swedish Orphan Biovitrum
Also known as: Direttore Dipartimento di Malattie Infettive | Sobi | Sobi AB | Sobi, Inc. | Sweden Orphan Biovitrum | Swedish Orphan Biovitrum | Swedish Orphan Biovitrum AB | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum GmbH | Swedish Orphan Biovitrum (SOBI)
Highest phase reached
Phase 4
Acquired by Advent International on Sep 8, 2021
Timeline
2010s
- Jan 1, 2010
Swedish Orphan Biovitrum— Founded
- Jan 1, 2010
Biovitrum AB— Acquired
- Jan 1, 2010
Swedish Orphan— Acquired
- Apr 22, 2016
nitisinone— NDA Secondary Org
- Jun 12, 2019
NovImmune SA— Acquired
- Sep 30, 2019
Dova Pharmaceuticals— Acquired
2020s
- Sep 8, 2021
Advent International— Acquired By
- Jun 26, 2023
CTI BioPharma— Acquired
- Dec 15, 2025
Arthrosi Therapeutics— Acquired
Drugs by trial phase (93 distinct, 184 trials)
Phase 4 (3 own, 3 via acquisition)
Phase 3 (9 own, 19 via acquisition)
- ibritumomab tiuxetan
- coagulation factor ix (Recombinant)
- prednisone
- antihemophilic factor viii (Recombinant), Fc-fusion protein
- gemcitabine
- paclitaxel
- nitisinone
- vincristine
- pixuvri
- ifosfamide
- carboplatin
- coagulation factor ix (Recombinant), Fc-fusion protein
- bile-salt-stimulated lipase
- immune globulin (human)
- cyclophosphamide
- +13 more
Phase 2 (13 own, 33 via acquisition)
Phase 1 (2 own, 11 via acquisition)
Indications
Studied for
- Arthritis
- Arthritis, Gouty
- Arthritis, Juvenile
- Carcinoma, Non-Small-Cell Lung
- Cystic Fibrosis
- Deglutition Disorders
- Ear Diseases
- Exocrine Pancreatic Insufficiency
- Fibrosis
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hemophilia A
- Hemophilia B
- Infections
- Labyrinth Diseases
- Labyrinthitis
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Mucocutaneous Lymph Node Syndrome
- Mucopolysaccharidoses
- Mucopolysaccharidosis III
- Mucositis
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Plasma Cell
- Neuralgia
- Neurotoxicity Syndromes
- Premature Birth
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Signs and Symptoms, Respiratory
- Stevens-Johnson Syndrome
- Still's Disease, Adult-Onset
- Stomatitis
- Tyrosinemias
Marketed drugs (5)
Subsidiaries (6 direct, 9 total across the full acquisition tree)
Recent trials (50)
- NCT07148947CollaboratorPhase 2Feb 1, 2026
- NCT07244419CollaboratorEarly Phase 1Dec 31, 2025
- NCT07033598CollaboratorPhase 2Dec 31, 2025
- NCT06986174CollaboratorPhase 2Nov 30, 2025
- NCT07197307CollaboratorPhase 2Oct 15, 2025
- NCT06782373Lead sponsorPhase 2May 31, 2025
- NCT06782373OfficialPhase 2May 31, 2025
- NCT06940830OfficialPhase 4May 21, 2025
- NCT06940830Lead sponsorPhase 4May 21, 2025
- NCT06716814OfficialPhase 3Jan 31, 2025
- NCT06716814Lead sponsorPhase 3Jan 31, 2025
- NCT06752850OfficialPhase 4Dec 19, 2024
- NCT06752850Lead sponsorPhase 4Dec 19, 2024
- NCT06579144Lead sponsorPhase 1Nov 30, 2024
- NCT06579144OfficialPhase 1Nov 30, 2024
Details
- Founded
- Stockholm, SE Jan 1, 2010
- Last known activity
- Feb 1, 2026